Quick Answer
Calidi Biotherapeutics, Inc. reported Shares Outstanding of 7.22 million shares for fiscal year 2025.
Calidi Biotherapeutics, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 7.22M | +317.2% |
| 2024 | 1.73M | -51.3% |
| 2023 | 3.55M | -58.6% |
| 2022 | 8.58M | -62.7% |
| 2021 | 23.00M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 6.91M | -25.8% | +140.1% |
| June 30, 2025 | 2.88M | -55.5% | -91.0% |
| March 31, 2025 | 31.79M | -11.0% | +1737.7% |
| December 31, 2024 | 1.73M | -51.3% | -81.4% |
| September 30, 2024 | 9.31M | -73.7% | +43.9% |
| June 30, 2024 | 6.47M | — | -81.9% |
| March 31, 2024 | 35.73M | — | +905.8% |
| December 31, 2023 | 3.55M | -58.6% | -90.0% |
- Calidi Biotherapeutics, Inc. showed an increase of +317.2% in Shares Outstanding compared to the prior fiscal year.
- Over the 2021–2025 period, Calidi Biotherapeutics, Inc.’s shares outstanding has declined by 68.6% (from 23.00 million shares to 7.22 million shares).
- The most recent figure is from Calidi Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: